Paper Details

  1. Home
  2. Paper Details

Dose-dependent effects of rosuvastatin on the plasma sphingolipidome and phospholipidome in the metabolic syndrome.

Author: BarrettP Hugh R, ChanDick C, MeiklePeter J, NgTheodore W K, OoiEsther M M, WattsGerald F, WeirJacquelyn M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Rosuvastatin dose-dependently lowers plasma sphingolipids and phospholipids, independent of low-density lipoprotein lowering, in men with the metabolic syndrome.
Paper Details　
Original Abstract of the Article :
CONTEXT: Statins are effective cholesterol-lowering agents that reduce cardiovascular disease risk but also have pleiotropic effects that may extend to other lipid classes. OBJECTIVE: The purpose of this article was to investigate, in a post hoc analysis, the dose-dependent effects of rosuvastatin ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1210/jc.2014-1665

データ提供：米国国立医学図書館（NLM）

Rosuvastatin: A Cholesterol-Lowering Drug with Broad Impact

Rosuvastatin, a widely prescribed [statin drug], is known for its effectiveness in lowering cholesterol levels and reducing cardiovascular risk. This study takes a closer look at the [dose-dependent effects] of rosuvastatin on a broader range of lipids in individuals with the metabolic syndrome. The authors investigated the impact of rosuvastatin on [plasma sphingolipids and phospholipids], providing valuable insights into the potential pleiotropic effects of this drug beyond cholesterol lowering.

Rosuvastatin's Reach: Beyond Cholesterol

The study found that rosuvastatin, in a dose-dependent manner, significantly reduced levels of [sphingolipids and phospholipids] in individuals with the metabolic syndrome. These findings suggest that rosuvastatin may have broader therapeutic benefits than previously recognized.

Navigating the Desert of Lipids: Understanding the Complexities

This research highlights the complex interplay of lipids in the body and the importance of understanding the broader impact of medications on these crucial molecules.

Dr.Camel's Conclusion

The desert of lipid metabolism is vast and complex, with each molecule playing a critical role in maintaining health. This study sheds light on the multifaceted effects of rosuvastatin, suggesting that this drug may offer broader benefits than previously known. As we continue to explore the desert of lipid research, we can expect to discover even more intricate connections between lipids, health, and disease.

Date :
  1. Date Completed 2015-01-16
  2. Date Revised 2017-11-16
Further Info :

Pubmed ID

25140396

DOI: Digital Object Identifier

10.1210/jc.2014-1665

Related Literature

Article Analysis
・Effective treatment of cholesterol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.